Abstract:Simple Summary Although twice-daily concurrent chemoradiotherapy for limited-stage small-cell lung cancer (LS-SCLC) is still the standard treatment, this regimen is inconvenient and not universally adopted across different institutions. Therefore, the optimal radiation dose and fractions are still under investigation. A once-daily hypofractionated schedule may be suitable for LS-SCLC patients, and more and more hypofractionated schedule studies are being performed. However, few studies have investigated the efficacy and toxicities of sequential chemotherapy and hypofractionated radiotherapy compared with the concurrent twice-daily schedule. Our evaluation of sequential hypofractionated and twice-daily concurrent chemoradiotherapy schedules before and after propensity score-matched analysis (PSM) for LS-SCLC revealed a comparable survival and less toxicity. The sequential hypofractionated schedule may be used as an alternative to concurrent twice-daily regimens. Background: As there are no randomized trials comparing twice-daily with sequential hypofractionated (sequential hypo) radiotherapy regimens for limited-stage small-cell lung cancer (LS-SCLC). This study aimed to compare these two regimens for LS-SCLC by propensity score-matched analysis (PSM). Methods: We retrospectively analyzed 108 LS-SCLC patients between January 2015 and July 2019. All patients received concurrent twice-daily or sequential hypo radiotherapy. The survival, failure patterns, and toxicities were evaluated before and after PSM. Results: Before PSM, multivariate analysis showed that patients treated with sequential hypo had a significantly better overall survival (OS) and distant metastasis-free survival (DMFS) (HR = 0.353, p = 0.009; HR = 0.483, p = 0.039, respectively). Total radiotherapy time >= 24 days and stage III (HR = 2.454, p = 0.004; HR = 2.310, p = 0.004, respectively) were poor prognostic indicators for OS. Patients with a total radiotherapy time >= 24 days and N2-3 were more likely to recur than others (HR = 1.774, p = 0.048; HR = 2.369, p = 0.047, respectively). N2-3 (HR = 3.032, p = 0.011) was a poor prognostic indicator for DMFS. After PSM, being aged >= 65 years was associated with poorer OS, relapse-free survival (RFS) and DMFS (p < 0.05). A total radiotherapy time of >= 24 days was a poor prognostic indicator for OS and RFS (HR = 2.671, p = 0.046; HR = 2.370, p = 0.054, respectively). Although there was no significant difference, the patients in the sequential hypo group had a trend towards a better OS. The failure pattern between the two groups showed no difference. More patients had grade 1-2 esophagitis in the twice-daily group (p = 0.001). Conclusions: After propensity matching, no difference was shown in survival and failure. The sequential hypo schedule was associated with comparable survival and less toxicity and may be used as an alternative to concurrent twice-daily regimens.

Concurrent Versus Sequential Chemotherapy With Hypofractionated Radiotherapy In Patients With Inoperable Locally Advanced Non-Small Cell Lung Cancer

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

A Comparasion of Response Between Concurrent Chemoradiotherapy and Sequential Chemoradiotherapy for 67 Cases with Locally Advanced Non-small Cell Lung Cancer

Comparison of Surgeries Plus Perioperative and Postoperative Chemotherapies in Chinese Pn2 Patients with Non-Small Cell Lung Cancer: A Real-World Observational Study.

Sequential Chemoradiotherapy with Accelerated Hypofractionated Radiotherapy Compared to Concurrent Chemoradiotherapy with Standard Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer.

[Clinical Trial of Concurrent Low-Dose Chemotherapy Plus Radiation Vs Sequential Chemoradiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer].

Concurrent Adjuvant Radiochemotherapy Versus Standard Chemotherapy Followed by Radiotherapy in Operable Breast Cancer after Breast Conserving Therapy: A Meta-Analysis.

Comparison of Clinical Efficacy of Radiotherapy Concurrent with Chemotherapy and Sequential Therapy for Locally Advanced Non-Small-Cell Lung Cancer

Non‐conventional Radiotherapy Versus Conventional Radiotherapy for Inoperable Non‐small‐cell Lung Cancer: A Meta‐analysis of Randomized Clinical Trials

Effects of Concurrent Chemoradiotherapy and Sequential Radiotherapy and Chemotherapy on Progression-free Survival in Patients with Non-small Cell Lung Cancer

[Weekly Paclitaxel and Carboplatin with Concurrent Three Dimensional Conformal Radiotherapy for Locally Advanced Non Small Cell Lung Cancer].

Curative Effects, Prognostic Factors, and Adverse Reactions of Different Treatment Modalities of Chemotherapy in Patients with Non-Small Cell Lung Cancer

A Network Meta-Analysis for Efficacies and Toxicities of Different Concurrent Chemoradiotherapy Regimens in the Treatment of Locally Advanced Non-Small Cell Lung Cancer

Sequential or concomitant chemotherapy with hypofractionated radiotherapy for locally advanced non-small cell lung cancer: a meta-analysis of randomized trials

Standardization of concurrent radiochemotherapy in locally advanced NSCLC

Clinical outcome of concurrent chemo-radiotherapy for patients with stage Ⅳ non-small cell lung cancer

Sequential Hypofractionated versus Concurrent Twice-Daily Radiotherapy for Limited-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis

Clinical outcome of concurrent chemo-radiotherapy for patients with stage IV non-small cell lung cancer

Comparisons of two chemoradiotherapy regimens for locally advanced non-squamous and non-small cell lung cancer

Concurrent Chemoradiotherapy with Original Chemotherapy Regimens May Not Be Suitable for Patients Who Failed to Respond to Induction Chemotherapy in Limited-stage Small Cell Lung Cancer

The survival impact of concurrent chemotherapy and primary tumor radiotherapy on stage IV squamous non-small-cell lung cancer